Turnstone Biologics (NASDAQ:TSBX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter.
Turnstone Biologics Stock Performance
Shares of TSBX stock opened at $0.39 on Wednesday. Turnstone Biologics has a 12 month low of $0.34 and a 12 month high of $3.88. The stock has a market cap of $9.11 million, a PE ratio of -0.12 and a beta of 2.04. The company’s fifty day moving average price is $0.42 and its 200-day moving average price is $0.49.
Analyst Ratings Changes
Separately, Piper Sandler cut shares of Turnstone Biologics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $3.75 to $0.40 in a research note on Wednesday, February 5th.
About Turnstone Biologics
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.
See Also
- Five stocks we like better than Turnstone Biologics
- 5 discounted opportunities for dividend growth investors
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Insider Trading – What You Need to Know
- 3 Must-Own Stocks to Build Wealth This Decade
- NYSE Stocks Give Investors a Variety of Quality Options
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
